Glucotrack / Integrity Applications, Inc. — Q1 2014 10-Q
Entity note: The filing identifies the registrant as Integrity Applications, Inc.; GlucoTrack is its product. The supplied company metadata names Glucotrack, Inc., so investors should confirm the filing is for the intended issuer.
Business context and reporting period
For the three months ended March 31, 2014, the company was a development-stage medical-device business developing the GlucoTrack DF-F, a non-invasive glucose monitor for home use. It had received CE Mark approval in June 2013, but had not begun sales and did not have U.S. approval. The filing says it had no operating revenue from inception.
Financial results and position
| Metric | Q1 2014 | Q1 2013 / prior date |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $451,084 | $504,245 |
| Selling, marketing and G&A expense | $436,102 | $183,579 |
| Operating loss | $887,186 | $687,824 |
| Financing income (expense), net | $150,267 income | $655,771 expense |
| Net loss | $736,919 | $1,343,595 |
| Loss per share, basic and diluted | $0.16 | $0.25 |
| Net cash used in operating activities | $688,269 | $645,377 |
At March 31, 2014, cash and cash equivalents were $1.62 million, down from $2.39 million at December 31, 2013. Current assets were $1.71 million and current liabilities $506,000. Total liabilities were $9.50 million, including $685,000 in long-term stockholder loans and an $8.07 million warrant liability. Convertible preferred stock of $4.36 million was presented as temporary equity; stockholders’ deficit was $11.87 million. The filing reports no operating margin or debt-to-equity measure.
Changes versus the prior comparable period
- Net loss narrowed by about $607,000, largely as financing results shifted from expense to income, including a $145,870 gain from the change in fair value of down-round-protected warrants in Q1 2014.
- Operating loss increased about $199,000: R&D expense declined by $53,000, while selling, marketing and G&A expense rose by $253,000. Management attributed the shifts to reallocating resources toward marketing and higher professional, public-company, salary and travel costs.
- Operating cash use increased by about $43,000. The prior-year quarter included $5.44 million of net financing proceeds; Q1 2014 had no capital raised and paid $92,674 in preferred dividends.
Outlook, risks and unusual items
- Management estimated that cash at the report date would fund operations for approximately four months; it said additional capital would be needed thereafter, potentially sooner if spending or plans changed. Cash was approximately $1.3 million on May 8, 2014.
- The company expected sales to begin in certain distributor markets during 2014, but had not yet commenced sales. It also expected to begin U.S. clinical trials during 2014 if its protocol was approved by the FDA. These are forward-looking plans, not guaranteed outcomes.
- Management expected R&D spending to remain at similar levels through the rest of 2014, subject to resources and development needs, and expected selling, marketing and G&A costs to increase.
- The filing and auditor discussion identify substantial doubt about the company’s ability to continue as a going concern. The company depended on external financing, and there was no assurance it could obtain sufficient funding. Financial statements include no adjustments for the outcome of this uncertainty.
- Other risks include product-development completion, market acceptance, competition, technological change, and the need for further capital. Down-round warrant valuation is a Level 3 estimate using a binomial model; changes in its fair value can materially affect reported financing results.
- Future product sales are subject to royalties to Israel’s Office of the Chief Scientist, at 3%–5% of proceeds until approximately $93,462 plus interest is repaid. Stockholder loans are generally not repayable until the company records annual accounting profit, subject to stated terms.
- The filing reports no off-balance-sheet arrangements and no material impact from adopting the cited foreign-currency accounting update.
Important facts for investors to verify
- Whether this Integrity Applications, Inc. filing corresponds to the issuer identified in the request as Glucotrack, Inc.
- Current cash, burn rate, financing progress and the company’s ability to continue beyond the stated approximate four-month runway.
- Actual timing and status of distributor launches, manufacturing arrangements, FDA protocol approval and U.S. clinical trials.
- Terms and potential effects of preferred stock, dividends, stockholder loans and down-round-protected warrants, including dilution and warrant-liability valuation.
- Whether sales royalties, product-development costs, regulatory requirements or market acceptance affect the anticipated commercialization plan.